1. Terevnikov V, Joffe G, Stenberg JH. Randomized controlled trials of add-on antidepressants in schizophrenia. Int J Neuropsychopharmacol. 2015;18(9):pyv049.
2. Tiihonen J, Suokas JT, Suvisaari JM, Haukka J, Korhonen P. Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. Arch Gen Psychiatry. 2012;69(5):476–83.
3. Ogino S, Miyamoto S, Miyake N, Yamaguchi N. Benefits and limits of anticholinergic use in schizophrenia: focusing on its effect on cognitive function. Psychiatry Clin Neurosci. 2014;68(1):37–49.
4. Yogaratnam J, Biswas N, Vadivel R, Jacob R. Metabolic complications of schizophrenia and antipsychotic medications-an updated review. East Asian Arch Psychiatry. 2013;23(1):21–8.
5. Scigliano G, Ronchetti G. Antipsychotic-induced metabolic and cardiovascular side effects in schizophrenia: a novel mechanistic hypothesis. CNS Drugs. 2013;27(4):249–57.
6. Takahashi T, Uchida H, John M, Hirano J, Watanabe K, Mimura M et al The impact of prolactin-raising antipsychotics on bone mineral density in patients with schizophrenia: findings from a longitudinal observational cohort. Schizophr Res. 2013;147(2–3):383–6.
7. Fleischhacker WW, Uchida H. Critical review of antipsychotic polypharmacy in the treatment of schizophrenia. Int J Neuropsychopharmacol. 2014;17(7):1083–93.
8. Joukamaa M, HeliÖvaara M, Knekt P, Aromaa A, Raitasalo R, Lehtinen V. Schizophrenia, neuroleptic medication and mortality. Br J Psychiatry. 2006;188(2):122–7.
9. Kishimoto T, Watanabe K, Uchida H, Mimura M, Kane JM, Correll CU. Antipsychotic polypharmacy: a Japanese survey of prescribers’ attitudes and rationales. Psychiatry Res. 2013;209(3):406–11.
10. Sim K, Su A, Fujii S, Yang S-Y, Chong M-Y, Ungvari GS et al Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia. Br J Clin Pharmacol. 2004;58(2):178–83.
11. Kochi K, Sato I, Nishiyama C, Tanaka-Mizuno S, Doi Y, Arai M et al Trends in antipsychotic prescriptions for Japanese outpatients during 2006–2012: a descriptive epidemiological study. Pharmacoepidemiol Drug Saf. 2017;26(6):642–56.
12. Okumura Y, Togo T, Fujita J. Trends in use of psychotropic medications among patients treated with cholinesterase inhibitors in Japan from 2002 to 2010. Int Psychogeriatr. 2015;27(3):407–15.
13. Yoshio T. The trend for megadose polypharmacy in antipsychotic pharmacotherapy: a prescription survey conducted by the psychiatric clinical pharmacy research group. Seishin Shinkeigaku Zasshi. 2012;114(6):690–5.
14. Gallego JA, Bonetti J, Zhang J, Kane JM, Correll CU. Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res. 1970s;138(1):18–28.
15. Okumura Y, Ito H, Kobayashi M, Mayahara K, Matsumoto Y, Hirakawa J. Prevalence of diabetes and antipsychotic prescription patterns in patients with schizophrenia: a nationwide retrospective cohort study. Schizophr Res. 2010;119(1–3):145–52.
16. Xiang Y-T, Li Y, Correll CU, Ungvari GS, Chiu HFK, Lai KYC et al Common use of high doses of antipsychotic medications in older Asian patients with schizophrenia (2001–2009). Int J Geriatr Psychiatry. 2014;29(4):359–66.
17. Ministry of Health, Labour and Welfare of Japan [internet] A vision for reforming mental health and welfare services 2004 [Cited Feb 6 2018] Available from http://www.mhlw.go.jp/topics/2004/09/dl/ tp0902-1a.pdf
18. Ministry of Health, Labour and Welfare of Japan [internet] Further reform of health and welfare services for persons with mental illness 2009 [Cited Feb 6 2018]. Available from http://www.mhlw. go.jp/shingi/2009/09/dl/s0924-2a.pdf
19. Ministry of Health, Labour and Welfare of Japan [internet] Summary of patient survey 2011. 2011 [Cited Feb 6 2018]. Available from http://www.mhlw.go.jp/toukei/saikin/hw/kanja/11/dl/toukei.pdf
20. Inada T, Inagaki A. Psychotropic dose equivalence in Japan. Psychiatry Clin Neurosci. 2015;69(8):440–7.
21. Young LT. What exactly is a mood stabilizer? J Psychiatry Neurosci. 2004;29(2):87–8.
22. Inagaki A, Inada T. Dose equivalence of psychotropic drugs. Part XX: dose equivalence of injectable antipsychotics. J Clin Psychopharmacol. 2007;10(2):373–7.
23. Inagaki A, Inada T. Dose equivalence of psychotropic drugs. Part XXII: Dose equivalence of depot antipsychotics III: risperidon long-acting injection. J Clin Psychopharmacol. 2010;13:1349–4353.
24. Inagaki A, Inada T. Dose equivalence of psychotropic drugs, Part XXI: Dose equivalence of novel antipsychotics: Blonanserin. J Clin Psychopharmacol. 2008;11:887–90.
25. DosReis S, Zito JM, Buchanan RW, Lehman AF. Antipsychotic dosing and concurrent psychotropic treatments for Medicaid-insured individuals with schizophrenia. Schizophr Bull. 2002;28(4):607–17.
26. Ito H, Koyama A, Higuchi T. Polypharmacy and excessive dosing: psychiatrists’ perceptions of antipsychotic drug prescription. Br J Psychiatry. 2005;187(3):243–7.
27. Sim K, Su HC, Fujii S, Yang S-Y, Chong M-Y, Ungvari G et al Highdose antipsychotic use in schizophrenia: a comparison between the 2001 and 2004 Research on East Asia Psychotropic Prescription (REAP) studies. Br J Clin Pharmacol. 2009;67(1):110–7.
28. Ministry of Education, Culture, Sports, Science and Technology, Ministry of Health, Labour and Welfare of Japan [internet] Ethical guidelines for epidemiological research June 2002 [Cited Mar 7 2017]. Available from https://www.mhlw.go.jp/seikakunitsuite/ bunya/hokabunya/kenkyuujigyou/i-kenkyu/dl/02-02.pdf
29. Xiang Y-T, Dickerson F, Kreyenbuhl J, Ungvari GS, Wang C-Y, Si TM et al Prescribing patterns of low doses of antipsychotic medications in older Asian patients with schizophrenia, 2001–2009. Int Psychogeriatr. 2012;24(6):1002–8.
30. Taylor D, Paton C, Kapur S. The Maudsley prescribing guidelines. London: CRC Press; 2009.
31. Andreasen NC, Pressler M, Nopoulos P, Miller D, Ho BC. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol Psychiatry. 2010;67(3):255–62.
32. Ministry of Health, Labour and Welfare of Japan [internet] A study on actual condition on psychotropic drug prescription using medical fee compensation data 2010 [Cited Jun 13 2018]. Available from http://www.ncnp.go.jp/tmc/pdf/22_report02.pdf
33. Okumura Y, Noda H, Ito H. Prescription pattern of antipsychotics in schizophrenia patients throughout Japan: Utilization of National Database. Jpn J Clin Psychopharmacol. 2013;9:1201–5.
34. Armstrong KS, Temmingh H. Prevalence of and factors associated with antipsychotic polypharmacy in patients with serious mental illness: findings from a cross-sectional study in an upper-middle-income country. Rev Bras Psiquiatr. 2017;39(4):293–301.
35. Zink M, Englisch S, Meyer-Lindenberg A. Polypharmacy in schizophrenia. Curr Opin Psychiatry. 2010;23(2):103–11.
36. Roh D, Chang JG, Kim CH, Cho HS, An SK, Jung YC. Antipsychotic polypharmacy and high-dose prescription in schizophrenia: a 5-year comparison. Aust N Z J Psychiatry. 2014;48(1):52–60.
37. Carnahan RM, Lund BC, Perry PJ, Chrischilles EA. Increased risk of extrapyramidal side-effect treatment associated with atypical antipsychotic polytherapy. Acta Psychiatr Scand. 2006;113(2):135–41.
38. Ministry of Health, Labour and Welfare of Japan [internet] Psychotropic drug use guideline corresponding to BPSD (2nd edition) 2016 [Cited Jun 13 2018]. Available from http://www.mhlw. go.jp/file/06-Seisakujouhou